(Reuters) – U.S. Democrat Senator Claire McCaskill has asked Kaleo Pharmaceuticals to justify the more than 550 percent surge in the price of its device to treat opioid overdoses, becoming the second senator to question Evzio’s $4,500 price tag.
Evzio contains the overdose-reversing drug naloxone and can be used in emergencies by people without medical training. Privately held Kaleo has raised the price of a twin-pack to $4,500, from $690 in 2014, according to a Kaiser Health News report.
The concerns over Evzio’s price comes at a time when pharmaceutical companies are facing intense scrutiny over “price-gouging,” and as lawmakers struggle with the epidemic of opioid abuse. The Centers for Disease Control and Prevention estimates at least 91 Americans succumb every day to opioid overdose, which experts partly blame on unrestricted painkiller prescriptions.